BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 19562642)

  • 1. PDE10A inhibitors: an assessment of the current CNS drug discovery landscape.
    Chappie T; Humphrey J; Menniti F; Schmidt C
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):458-67. PubMed ID: 19562642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.
    Menniti FS; Chappie TA; Humphrey JM; Schmidt CJ
    Curr Opin Investig Drugs; 2007 Jan; 8(1):54-9. PubMed ID: 17263185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.
    Siuciak JA; Chapin DS; Harms JF; Lebel LA; McCarthy SA; Chambers L; Shrikhande A; Wong S; Menniti FS; Schmidt CJ
    Neuropharmacology; 2006 Aug; 51(2):386-96. PubMed ID: 16780899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patented PDE10A inhibitors: novel compounds since 2007.
    Kehler J; Kilburn JP
    Expert Opin Ther Pat; 2009 Dec; 19(12):1715-25. PubMed ID: 19939189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.
    Höfgen N; Stange H; Schindler R; Lankau HJ; Grunwald C; Langen B; Egerland U; Tremmel P; Pangalos MN; Marquis KL; Hage T; Harrison BL; Malamas MS; Brandon NJ; Kronbach T
    J Med Chem; 2010 Jun; 53(11):4399-411. PubMed ID: 20450197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 4-hydroxy-1,6-naphthyridine-3-carbonitrile derivatives as novel PDE10A inhibitors.
    Bauer U; Giordanetto F; Bauer M; O'Mahony G; Johansson KE; Knecht W; Hartleib-Geschwindner J; Carlsson ET; Enroth C
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1944-8. PubMed ID: 22321214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.
    Schmidt CJ; Chapin DS; Cianfrogna J; Corman ML; Hajos M; Harms JF; Hoffman WE; Lebel LA; McCarthy SA; Nelson FR; Proulx-LaFrance C; Majchrzak MJ; Ramirez AD; Schmidt K; Seymour PA; Siuciak JA; Tingley FD; Williams RD; Verhoest PR; Menniti FS
    J Pharmacol Exp Ther; 2008 May; 325(2):681-90. PubMed ID: 18287214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.
    Smith SM; Uslaner JM; Cox CD; Huszar SL; Cannon CE; Vardigan JD; Eddins D; Toolan DM; Kandebo M; Yao L; Raheem IT; Schreier JD; Breslin MJ; Coleman PJ; Renger JJ
    Neuropharmacology; 2013 Jan; 64():215-23. PubMed ID: 22750078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.
    Verhoest PR; Chapin DS; Corman M; Fonseca K; Harms JF; Hou X; Marr ES; Menniti FS; Nelson F; O'Connor R; Pandit J; Proulx-Lafrance C; Schmidt AW; Schmidt CJ; Suiciak JA; Liras S
    J Med Chem; 2009 Aug; 52(16):5188-96. PubMed ID: 19630403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel 2-methoxyacylhydrazones as potent, selective PDE10A inhibitors with activity in animal models of schizophrenia.
    Cutshall NS; Onrust R; Rohde A; Gragerov S; Hamilton L; Harbol K; Shen HR; McKee S; Zuta C; Gragerova G; Florio V; Wheeler TN; Gage JL
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5595-9. PubMed ID: 22841436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.
    Chappie TA; Humphrey JM; Allen MP; Estep KG; Fox CB; Lebel LA; Liras S; Marr ES; Menniti FS; Pandit J; Schmidt CJ; Tu M; Williams RD; Yang FV
    J Med Chem; 2007 Jan; 50(2):182-5. PubMed ID: 17228859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A.
    Strick CA; James LC; Fox CB; Seeger TF; Menniti FS; Schmidt CJ
    Neuropharmacology; 2010 Feb; 58(2):444-51. PubMed ID: 19765598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of benzo[d]imidazo[5,1-b]thiazole as a new class of phosphodiesterase 10A inhibitors.
    Banerjee A; Narayana L; Raje FA; Pisal DV; Kadam PA; Gullapalli S; Kumar H; More SV; Bajpai M; Sangana RR; Jadhav S; Gudi GS; Khairatkar-Joshi N; Merugu RR; Voleti SR; Gharat LA
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6747-54. PubMed ID: 24231362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PDE10A inhibitors: novel therapeutic drugs for schizophrenia.
    Kehler J; Nielsen J
    Curr Pharm Des; 2011; 17(2):137-50. PubMed ID: 21355834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase 10A inhibitors: a 2009 - 2012 patent update.
    Kehler J
    Expert Opin Ther Pat; 2013 Jan; 23(1):31-45. PubMed ID: 23210904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of natural product inhibitors of phosphodiesterase 10A as novel therapeutic drug for schizophrenia using a multistep virtual screening.
    Al-Nema M; Gaurav A; Akowuah G
    Comput Biol Chem; 2018 Dec; 77():52-63. PubMed ID: 30240986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Understanding of PDE10A in the Modulation of Basal Ganglia Circuitry.
    Schülke JP; Brandon NJ
    Adv Neurobiol; 2017; 17():15-43. PubMed ID: 28956328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 2: Focus on Schizophrenia.
    Świerczek A; Jankowska A; Chłoń-Rzepa G; Pawłowski M; Wyska E
    Curr Drug Targets; 2019; 20(16):1652-1669. PubMed ID: 31368871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of JNJ-42314415, a centrally active phosphodiesterase 10A (PDE10A) inhibitor: a comparison of PDE10A inhibitors with D2 receptor blockers as potential antipsychotic drugs.
    Megens AA; Hendrickx HM; Hens KA; Fonteyn I; Langlois X; Lenaerts I; Somers MV; de Boer P; Vanhoof G
    J Pharmacol Exp Ther; 2014 Apr; 349(1):138-54. PubMed ID: 24421319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice.
    Hebb AL; Robertson HA; Denovan-Wright EM
    Eur Neuropsychopharmacol; 2008 May; 18(5):339-63. PubMed ID: 17913473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.